Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registry - Warfarin cohort
Not Applicable
- Conditions
- on-valvular atrial fibrillation patients scheduled to undergo the catheter ablation procedure
- Registration Number
- JPRN-UMIN000015498
- Lead Sponsor
- Reimeikyo
- Brief Summary
The rates of thromboembolism and major bleeding events during the AF ablation perioperative period in Japanese patients treated with rivaroxaban was as low as in those treated with warfarin.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 550
Inclusion Criteria
Not provided
Exclusion Criteria
- Patients for whom catheter ablation for atrial fibrillation is contraindicated - Patients with a history of thromboembolism or myocardial infarction within 2 months prior to enrollment
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Composite of thromboembolic events and major bleedings within 1 month since catheter ablation procedure - Thromboembolic events; transient ischemic attack, ischemic stroke, non-CNS systemic embolism - Major bleeding: pericardial effusion requiring a drainage procedure (cardiac tamponade),puncture hematoma requiring surgery, other bleeding episodes requiring blood transfusion, intracranial hemorrhage
- Secondary Outcome Measures
Name Time Method - Thromboembolism within 1 month since catheter ablation procedure - Major bleeding within 1 month since catheter ablation procedure - Non-major bleeding within 1 month since catheter ablation procedure